UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes $7.99 Million Position in Indivior PLC $INDV

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Indivior PLC (NASDAQ:INDV) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 194,687 shares of the company’s stock, valued at approximately $7,988,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.16% of Indivior as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of INDV. Quarry LP acquired a new position in shares of Indivior during the 3rd quarter worth approximately $26,000. Raymond James Financial Inc. acquired a new stake in shares of Indivior in the second quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd raised its position in shares of Indivior by 72.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after buying an additional 460 shares in the last quarter. Rockefeller Capital Management L.P. boosted its stake in shares of Indivior by 512.4% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock valued at $46,000 after buying an additional 1,076 shares during the period. Finally, GAMMA Investing LLC bought a new stake in shares of Indivior in the second quarter valued at approximately $66,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Barclays lowered their price objective on Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 5th. Zacks Research downgraded Indivior from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 29th. Craig Hallum reissued a “buy” rating and set a $53.00 target price on shares of Indivior in a report on Tuesday, August 4th. Finally, Weiss Ratings upgraded Indivior from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday. Six investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, Indivior currently has an average rating of “Moderate Buy” and a consensus price target of $45.17.

Insider Buying and Selling

In related news, CAO Woodrow D. Anderson bought 1,500 shares of the business’s stock in a transaction on Thursday, August 27th. The shares were purchased at an average price of $35.69 per share, for a total transaction of $53,535.00. Following the completion of the transaction, the chief accounting officer directly owned 27,638 shares of the company’s stock, valued at approximately $986,400.22. This represents a 5.74% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, insider Christian Heidbreder sold 18,586 shares of the business’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $41.14, for a total transaction of $764,628.04. Following the sale, the insider directly owned 209,337 shares in the company, valued at approximately $8,612,124.18. The trade was a 8.15% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.74% of the stock is owned by corporate insiders.

Indivior Price Performance

NASDAQ:INDV opened at $34.94 on Tuesday. Indivior PLC has a twelve month low of $22.22 and a twelve month high of $42.81. The stock’s 50-day simple moving average is $38.64 and its 200 day simple moving average is $36.04. The firm has a market capitalization of $4.12 billion, a PE ratio of 12.52 and a beta of 0.82.

Indivior (NASDAQ:INDV) last posted its earnings results on Tuesday, June 30th. The company reported $5.75 EPS for the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%. The firm had revenue of $343.00 million during the quarter. On average, analysts anticipate that Indivior PLC will post 3.66 EPS for the current fiscal year.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.